Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: Formulation, characterization, and cytotoxicity studies

Nanoscale Research Letters

Volumn 6, Issue 1, 2011, Pages

  Sanna, Vanna ^a   Roggio, Anna Maria ^a   Posadino, Anna Maria ^b   Cossu, Annalisa ^b   Marceddu, Salvatore ^c   Mariani, Alberto ^b   Alzari, Valeria ^b   Uzzau, Sergio ^a,b   Pintus, Gianfranco ^b   Sechi, Mario ^b  

^a Porto Conte Ricerche Srl   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c INSTITUTE OF SCIENCES OF FOOD PRODUCTION   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCK COPOLYMERS; CELL CULTURE; CHEMOTHERAPY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISEASES; DRUG PRODUCTS; EFFICIENCY; NANOPARTICLES; NANOSYSTEMS; PARTICLE SIZE; PARTICLE SIZE ANALYSIS; SIZE DISTRIBUTION; TARGETED DRUG DELIVERY; UROLOGY; COPOLYMERS; ENCAPSULATION; ENZYME INHIBITION; PATIENT TREATMENT; POLYMERS; SURFACE ACTIVE AGENTS;

BIODEGRADABLE BLOCK COPOLYMERS; CONCENTRATION-DEPENDENT MANNERS; ENCAPSULATION EFFICIENCY; HUMAN PROSTATE CANCER CELLS; NANOPARTICULATE SYSTEM; NANOPRECIPITATION METHOD; POLY(LACTIDE-CO-CAPROLACTONE); POLYMERIC NANOPARTICLES; AVERAGE DIAMETER; CLINICAL EFFICACY; CLINICAL RESPONSE; CONCENTRATION-DEPENDENT; CRYSTALLINE STRUCTURE; DELIVERY SYSTEMS; DOCETAXEL; GROWTH INHIBITION; IN-VITRO; PLURONIC F-127; POLYMERIC MATERIAL; POLYMERIC MATRICES; PROSTATE CANCERS; RELEASE PROFILES; SIDE EFFECT; SPHERICAL SHAPE; SURFACTANT AGENTS; UNIMODAL PARTICLES;

CONTROLLED DRUG DELIVERY; DISEASES;

EID: 82655177897     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-6-260     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED:Docetaxel and estramustine compared with mitoxantrone and prednisonefor advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1152.
4. Petrylak DP: The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol 2006, 8:S48-S55.
5. Lee E, Kim H, Lee IH, Jon S: In vivo antitumor effects of chitosan- conjugated docetaxel after oral administration. J Control Release 2009, 140:79-85.
6. Musumeci T, Ventura C, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G: PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006, 325:172-179.
7. Zhang Z, Feng SS: Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
8. Zhang H, Cui W, Bei J, Wang S: Preparation of poly(lactide-co-glycolide- co-caprolactone) nanoparticles and their degradation behaviour in aqueous solution. Polym Degrad Stab 2006, 91:1929-1936.
9. Hans ML, Lowman AM: Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
10. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F: Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
11. Sahoo SK, Panyam J, Prabha S, Labhasetwar V: Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002, 82:105-114.
12. Khattak SF, Bhatia SR, Roberts SC: Pluronic F127 as a cell encapsulation material: utilization of membrane-stabilizing agents. Tissue Eng 2005, 11:974-983.
13. Moghimi SM, Hunter AC: Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 2000, 18:412-420.
14. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C, Sun H, Huang L: The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 2010, 6:170-178.
15. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 2003, 91:417-429
16. Fonseca C, Simoes S, Gaspar R: Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002, 83:273-286.
17. Cho K, Wang X, Nie S, Chen Z, Shin DM: Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
18. Mehta AK, Yadav KS, Sawant KK: Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv 2007, 4:185-193.
19. Korsmeyer RW, Gurney R, Doelker E, Buri P, Peppas NA: Mechanism of solute release from porous hydrophilic polymer. J Pharm Sci 1983, 15:25-35.
20. Jeong SI, Kim BS, Kang SW, Kwon JH, Lee YM, Kim SH, Kim YH: In vivo biocompatibilty and degradation behavior of elastic poly(L-lactide-co- epsilon-caprolactone) scaffolds. Biomaterials 2004, 25:5939-5946
21. Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, Wen X, Wei K, Gao X: Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release 2010, 147:278-288.
22. Panyam J, Labhasetwar V: Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003, 20:212-220.
23. Yoo HS, Park TG: Folate-receptor-targeted delivery of doxorubicin nano- aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004, 100:247-256.